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Abstract
Background: Strychnine-sensitive glycine receptors in many adult forebrain regions consist of
alpha2 + beta heteromeric channels. This subunit composition is distinct from the alpha1 + beta
channels found throughout the adult spinal cord. Unfortunately, the pharmacology of forebrain
alpha2beta receptors are poorly defined compared to 'neonatal' alpha2 homomeric channels or
'spinal' alpha1beta heteromers. In addition, the pharmacologic properties of native alpha2beta
glycine receptors have been generally distinct from receptors produced by heterologous
expression. To identify subtype-specific pharmacologic tools for the forebrain alpha2beta
receptors, it is important to identify a heterologous expression system that closely resembles these
native glycine-gated chloride channels.
Results: While exploring pharmacological properties of alpha2beta glycine receptors compared to
alpha2-homomers, we found that distinct heterologous expression systems appeared to
differentially influence partial agonist pharmacology. The β-amino acid taurine possessed 30–50%
efficacy for alpha2-containing receptor isoforms when expressed in HEK 293 cells. However,
taurine efficacy was dramatically reduced in L-cell fibroblasts. Similar results were obtained for β-
alanine. The efficacy of these partial agonists was also strongly reduced by the beta subunit. There
were no significant differences in apparent strychnine affinity values calculated from concentration-
response data between expression systems or subunit combinations. Nor did relative levels of
expression correlate with partial agonist efficacy when compared within or between several
different expression systems. Finally, disruption of the tubulin cytoskeleton reduced the efficacy of
partial agonists in a subunit-dependent, but system-independent, fashion.
Conclusions: Our results suggest that different heterologous expression systems can dramatically
influence the agonist pharmacology of strychnine-sensitive glycine receptors. In the systems
examine here, these effects are independent of both absolute expression level and any system-
related alterations in the agonist binding site. We conclude that complex interactions between
receptor composition and extrinsic factors may play a significant role in determining strychnine-
sensitive glycine receptor partial agonist pharmacology.
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Background
It has been well established that the amygdala is impor-
tant in the acquisition and maintenance of fear/anxiety-
related behaviors [1]. Strychnine-sensitive glycine recep-
tors have recently been found in the adult rat basolateral
amygdala (BLA) using whole cell and intracellular electro-
physiology [2,3]. Reverse transcription polymerase chain
reaction on whole BLA tissue and single cells revealed a
prominent expression of α2 mRNA; and these receptors
are likely to be α2β heteromers due to their low picrotoxin
sensitivity [4]. This finding is consistent with prominent
BLA 'general' immunoreactivity for α/β subunit protein
but no apparent α1-specific protein expression [3]. A sim-
ilar enrichment of α2/β heteromers is also evident in stri-
atal cholinergic interneurons [5]. It is quite possible then
that the α2β strychnine-sensitive glycine receptors present
in the adult BLA and other forebrain areas represents a
receptor population that could be functionally distin-
guished from those found in the spinal cord. Because the
BLA regulates a number of anxiety- or fear-related behav-
iors [6], it is possible that this population of strychnine-
sensitive glycine receptors may represent a novel thera-
peutic target for anxiety disorders. To insure that novel
α2β compounds possess an appropriate therapeutic index,
the pharmacology of these forebrain glycine receptors
must be elucidated and extensively compared with the
spinal isoform.
There have been conflicting reports regarding the details
of glycine receptor pharmacology when expressed in het-
erologous systems. For example, taurine acts as a partial
agonists (ca. 50% efficacy compared to glycine) for
GlyRα1 expressed in Xenopus ooctyes [7] whereas it shows
nearly full agonist efficacy for GlyRα1 expressed in HEK
293 cells [8]. Compared to GlyRα1, taurine efficacy is even
weaker for GlyRα2 (ca. 5–10% efficacy) when expressed in
Xenopus oocytes [7]. However, native GlyRα2β receptors
expressed by BLA neurons possess >50% efficacy for tau-
rine and almost full efficacy for β-alanine [2]. While these
results might initially be dismissed as expression system-
dependent phenomena, brain region-specific effects are
also evident in the literature. Taurine has markedly differ-
ent efficacies at glycine receptors expressed by isolated
adult lateral/basolateral amygdala neurons [2], adult
hypothalamic magnocellular neurons [9], and juvenile
spinal cord neurons [10]. It is therefore possible that the
mechanisms regulating brain region-specific effects are
related to those governing the divergence among heterol-
ogous expression systems. However, such mechanisms
have not been systematically investigated, despite their
potential usefulness in understanding region-to-region
pharmacologic heterogeneity evident for some native
receptors.
This study utilizes whole-cell patch clamp electrophysiol-
ogy to examine the influence of distinct heterologous
expression systems on the β-amino acid pharmacology of
glycine receptors composed of distinct subunit combina-
tions. We have focused on the α2 and α2β receptors since
these appear to be the predominate isoforms found in the
embryonic and adult forebrain, respectively. Our results
provide potentially important insight into the types of
mechanisms that may govern brain region-to-brain region
variation in glycine receptor pharmacology. Several
aspects of this work have appeared in abstract form
[11,12].
Results
Subunit- and system-dependent effects on glycine 
pharmacology
Given the variation of glycine receptor partial agonist
pharmacology in the literature, we specifically sought to
identify any role that expression system may play in their
pharmacological profiles. First, glycine concentration-
response relationships were established for GlyRα2, and
GluRα2/β in HEK-293 cells and in L-cell fibroblasts. Gly-
cine-gated responses for each receptor isoform were elic-
ited in a dose-dependent manner in both cell types (Fig.
1A). The apparent EC50 of glycine HEK cells was 221 µM
and 269 µM for α2 (n = 4–6) and α2β (n = 7–8), respec-
tively. GlyR subunits expressed in L-cells displayed a sim-
ilar pharmacological profile. However, the apparent
glycine EC50 of both GlyRα2 (446  µM, n = 5–7) and
GlyRα2β (667 µM, n = 4–8) appeared lower than apparent
affinities for the same subunits when expressed in L-cells.
Two-way ANOVA on the Log (EC50) values (Table 1) indi-
cated a significant effect of system (F = 20.01, P < 0.001).
However, the presence of the β-subunit did not signifi-
cantly affect glycine apparent affinity in either system nor
was there a significant interaction between system and
subunit composition. These results indicate that glycine is
less potent for receptors expressed in L cells compared to
HEK cells.
Subunit- and system-dependent effects on β-Alanine 
pharmacology
With the glycine pharmacological profile established, we
next examined the pharmacology of the partial agonists,
β-alanine and taurine. The efficacy and potency of these β-
amino acids were compared to glycine by normalizing the
current response at each concentration to a maximal gly-
cine response in that same cell. In HEK cells (Fig. 1B), the
average β-alanine EC50 values calculated from individual
cells were 770 µM (n = 6) and 570 µM (n = 7) for α2 and
α2/β receptors, respectively. In L-cells, β-alanine also elic-
ited currents in a dose-dependent manner. And, like gly-
cine, β-alanine appeared to be less potent in these cells
compared to HEK cells. EC50 values for α2 and α2/β recep-
tors were 2.0 mM (n = 8) and 2.9 mM (n = 7), respectively.BMC Pharmacology 2004, 4:16 http://www.biomedcentral.com/1471-2210/4/16
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Two-way ANOVA on LogEC50 values from these studies
indicate a significant effect of the expression system on β-
alanine potency (F = 43.52, P < 0.0001). There was a trend
for the presence of the β-subunit to influence potency but
this was not significant nor was there any significant inter-
action between expression system and subunit
composition.
β-alanine efficacy was also examined in these same exper-
iments by normalizing the maximal β-alanine response as
a fraction of a maximal glycine response. In HEK cells, the
α2 and α2β isoforms had efficacies of 80 ± 6% and 55 ±
7% of the maximal glycine response, respectively. A simi-
lar trend was noted in L-cells with the α2 and α2β isoform
with β-alanine efficacies being 39 ± 8% and 25 ± 5% of
the maximal glycine response. Two-way ANOVA analysis
of these data indicate that both expression system and
subunit composition had a significant influence on β-
alanine efficacy (F = 27.6, P < 0.0001 and F = 7.9, P < 0.01
respectively). There was no significant interaction
between these variables. These data demonstrate that the
presence of the β subunit reduced β-alanine efficacy of α2-
containing receptors and that this efficacy was substan-
tially smaller L-cells compared to HEK cells.
Subunit- and system-dependent effects on taurine 
pharmacology
Similar analysis of taurine pharmacology in HEK and L-
cells revealed more dramatic effects of system and subunit
on this partial agonist (Fig. 1C). In HEK cells, the apparent
EC50 for taurine was 501 µM for GlyRα2 (n = 9) and 2 mM
for GlyRα2β (n = 7). Because of its remarkably low efficacy
in L-cells (see below), we can only provide estimates of
taurine potency in this expression system. Regardless,
apparent taurine affinity for both GlyRα2 and GlyRα2β
expressed in L cells were ~3 mM for both isoforms (n = 4
and 7, respectively). We did not compare L cell data with
that obtained from HEK cells due to the uncertainty sur-
rounding the fits. However, there was no significant differ-
ence in apparent taurine potency between the α2 and α2β
receptors expressed in HEK cells (P >> 0.05, t-test).
Taurine efficacy was obviously quite different between the
two expression systems. In HEK cells, taurine efficacy was
48 ± 12% of glycine for GlyRα2 and 32 ± 4% of glycine for
the GlyRα2β isoform. Efficacy for these same receptors
was reduced to approximately 6 ± 1% and 5 ± 0.7% of gly-
cine when they were expressed in L-cells in these particu-
lar studies. The system difference was significant with two-
way ANOVA (F = 17.4, P < 0.001) with no substantial
effects of subunit composition or interactions between
these variables.
Glycine receptors expressed show expression-system  dependent agonist pharmacology Figure 1
Glycine receptors expressed show expression-system 
dependent agonist pharmacology. (A) Glycine has a reduced 
potency in L-cells compared to HEK cells. Glycine current 
responses were plotted versus the log concentration of gly-
cine and normalized to a maximal concentration of glycine 
(3–10 mM). Data are presented as mean ± SEM; 4 ≤ n ≤ 9 
cells for each concentration. Concentration response rela-
tionships for GlyRα2 (; EC50 = 221 µM) and GlyRα2β (❍ ; 
269 µM) in HEK cells and in L-cells (GlyRα2, ■ , 446 µM; 
GlyRα2β, ● ; 667 µM) were derived from logistic equation 
fits to individual cells. (B) β-alanine has both reduced appar-
ent affinity and efficacy for most glycine receptor isoforms 
transiently expressed in L-cells compared to HEK 293 cells. 
β-alanine apparent potency in HEK 293 cells was 717 µM for 
GlyRα2 (, n = 6) and 560 µM for GlyRα2β (❍ , n = 7). For L-
cells, β-alanine potency for GlyRα2 (■ , n = 5–8) was 1.61 mM 
and 1.79 mM for GlyRα2β (● , n = 7). Current responses 
were normalized to a maximal concentration of glycine (10 
mM). Note the reduced apparent efficacy of α2β receptors 
compared to the α2 homomeric isoforms. (C) Taurine has 
both reduced apparent affinity and efficacy to GlyRs tran-
siently expressed in L-cells compared to HEK 293 cells. Tau-
rine concentration-response relationship in HEK 293 for 
GlyRα2 (; 442 µM, n = 5–6) and GlyRα2β (❍ ; 1.25 mM, n = 
3–5). Taurine concentration-response relationship in L-cells 
yielded GlyRα2 (■ , n = 4) and GlyRα2β (● , n = 7) potencies 
estimated at ≥ 3 mM. Current responses were plotted versus 
the log concentration of taurine and normalized to a maximal 
concentration of glycine.
A
B
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Expression level and system-dependent pharmacology
The preceding results suggest that there may be a complex
interaction between subunit composition and the expres-
sion system in which the receptor is produced. Specifi-
cally, the system-dependent agonist pharmacology could
be related to differences in the relative expression levels
between various systems. Expression level has clearly been
demonstrated to influence agonist pharmacology for G
protein-coupled receptors (e.g. [13]), where the levels of
G-protein bound to receptor and thus the relative levels of
high affinity receptor can vary from system to system.
However, the influence of expression level on ligand-
gated channel function has not been extensively explored
(see Discussion). Unfortunately, it is problematic to com-
pare expression levels between HEK and L-cells since the
relative efficiency of transfection varied widely between
these systems. Indeed, liposome-mediated transfection is
remarkably efficient in HEK 293 cells (70–90% of cells
based on GFP fluorescence) but only marginally effective
in L-cells (10–20% of cells, not shown). To get around
these differences in transfection efficiency, we examined
the relative expression level of GlyRα2 protein using west-
ern analysis of total lysate derived from the same number
of GFP+ HEK 293 or L cells from transfected cultures (Fig.
2A). For this experiment, cells were harvested under native
conditions, GFP+  cells were counted, and volumes of
lysate corresponding to equivalent numbers of GFP+ cells
was loaded onto the gel. Western blots from two separate
experiments demonstrate that transfected HEK 293 cells
expressed 4- to 5-fold more GlyRα2 protein than trans-
fected L-cells. The mean optical density from the two
experiments was 83 ± 2 units for HEK cells and 17 ± 2
units for L-cells.
Maximal conductance is an independent measure of func-
tional expression and was also larger for both α2 and α2β
receptors expressed in HEK cells compared to receptors
expressed in L cells (Fig. 2B). Across all experiments where
maximal glycine concentrations were assayed, the
conductance of α2 receptors expressed in L-cells was 65 ±
11 nS and was 114 ± 21 nS in HEK cells. Similarly, L-cells
expressed  α2β receptors at 42 ± 9 nS while HEK cells
expressed this isoform at 104 ± 17 nS. Two-way ANOVA
using subunit and system as variables revealed a signifi-
cant effect of system (F = 15.4, P < 0.001) but not subunit,
nor was there a significant interaction between variables.
Results from both westerns and functional experiments
therefore indicate that relative expression levels of glycine
receptor were different between HEK and L-cells.
To further explore the interaction between expression
level and partial agonist efficacy, both current density and
taurine efficacy were compared for α2 and  α2β glycine
receptors in a number of different heterologous systems,
as well as for native receptors expressed in rat lateral/baso-
lateral amygdala. In addition to HEK and L-cells, the het-
erologous systems included mouse 3T3 fibroblasts and
MDCK kidney cells. α2β receptors expressed in mouse 3T3
fibroblasts had twice the current density (121 ± 34 pA/pF)
of the mouse L-cells (59 ± 19 pA/pF) but had a similar tau-
rine efficacy (13 ± 8% of glycine in 3T3 cells versus 8 ± 1%
in L-cells). Similarly, α2β receptors expressed in HEK293
cells had a current density similar to GlyRs expressed in
3T3 fibroblasts (115 ± 11 pA/pF) but had a taurine effi-
cacy compared to glycine of 48 ± 3%. This efficacy was
similar to glycine receptors expressed by acutely isolated
adult rat basolateral amygdala neurons (46 ± 5% of gly-
cine) although the current density in this native system
was only 57 ± 14 pA/pF. Note that the channels expressed
by these neurons are composed primarily of α2+β subu-
nits [4]. Canine kidney MDCK cells expressed the lowest
α2β current density (15 ± 5 pA/pF); yet the channels
expressed by this system had the highest taurine efficacy
of any cell tested (101+6%). For α2 GlyRs, the rank order
of glycine receptor density was 3T3 (111 ± 21 pA/pF)>
HEK cell (90 ± 11 pA/pF)> L-cell (50 ± 9 pA/pF); while the
Table 1: Agonist Pharmacology in HEK and L-cells.
GlyR α2 GlyR α2β
System log EC50 EC50 (mM) Efficacya log EC50 EC50 (mM) Efficacy
Glycine
HEK -3.67 ± 0.15 0.22 -- -3.55 ± 0.06 0.28 --
L-cells -3.36 ± 0.05 0.43 -- -3.17 ± 0.04 0.67 --
β-Alanine
HEK -3.12 ± 0.05 0.76 0.80 ± 0.06 -3.24 ± 0.03 0.57 0.55 ± 0.07
L-cells -2.71 ± 0.08b 1.93 0.39 ± 0.08 -2.59 ± 0.13 2.59 0.25 ± 0.05
Taurine
HEK -3.13 ± 0.12 0.74 0.48 ± 0.12 -2.67 ± 0.12 2.20 0.32 ± 0.05
L-cells ≥-3.00 ± 0.11c 1.00 0.06 ± 0.01 ≥-2.97 ± 0.20c 1.10 0.05 ± 0.01
a – efficacy relative to maximal glycine response b – p < 0.0001 for system but not subunit using two-way ANOVA c – estimate due to low efficacyBMC Pharmacology 2004, 4:16 http://www.biomedcentral.com/1471-2210/4/16
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Relative expression levels does not influence taurine efficacy Figure 2
Relative expression levels does not influence taurine efficacy. 
(A) HEK and L-cells were co-transfected with the GlyRα2 
subunit and GFP. Relative expression levels of α2-protein 
were examined using western blot analysis of total lysate 
from equal numbers of GFP+ HEK and L-cells. α2 protein was 
4- to 5-fold greater in GFP+ HEK cells than in GFP+ L-cells. 
(B) Maximal glycine conductance across all experiments was 
significantly lower in L-cells compared to HEK cells, although 
only by about 2-fold. This may indicate that a significant 
amount of α2 protein in HEK cells (A) is present in a non-
functional form or not associated with the plasma mem-
brane. (C) Glycine current density vs. taurine efficacy in dif-
ferent cell lines expressing α2 (open symbols), α2β glycine 
receptors (closed symbols), and in isolated neurons from the 
adult rat basolateral amygdala. The correlation coefficient 
between glycine current density and taurine efficacy was 0.14 
and was not significantly greater than zero (P >> 0.05). There 
was also no correlation (R2 = 0.01 to 0.3) between glycine 
current density and taurine efficacy when comparing individ-
ual cells within each of these systems.
GFP+ Cells
HEK L HEK L
GlyR α α α α2 IR
2X103 1X103
A
B
C
Glycine receptors expressed in different expression systems  have similar 'functional' strychnine binding Figure 3
Glycine receptors expressed in different expression systems 
have similar 'functional' strychnine binding. Cells were pre-
treated for 30 seconds with strychnine alone then exposed 
to a strychnine admixture with an EC50 concentration of gly-
cine. (A) Strychnine-mediated inhibition of glycine-gated cur-
rents of GlyRα2 homomers expressed in HEK 293 (; IC50 = 
78.2 ± 13.5 nM) and L-cells (■ ; 33.1 ± 6.3 nM). (B) Strych-
nine-mediated inhibition of glycine-gated currents of 
GlyRα2β heteromers expressed in HEK 293 (❍ ; 37.9 ± 7.9 
nM) and L-cells (● ; 23.2 ± 4.6 nM). (C) Functional KB values 
were calculated from IC50 values for individual cells using the 
Cheng-Prusoff relationship and glycine affinity/Hillslope data 
represented in Figure 1. Average KB values are shown for 
each subunit combination in the two expression systems. 
There was no significant effect of subunit compositions or 
expression system.
A
B
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rank order of taurine efficacy for these same receptors was
HEK (74 ± 9%)> 3T3 (23+7%)> L-cells (11 ± 2%). Across
all subunit combinations and systems, there was no sig-
nificant correlation (R2 = 0.14, P >> 0.05) between taurine
efficacy and glycine current density (Fig. 5C). Indeed, no
correlation between expression level and taurine efficacy
was evident within any given population of cells whether
the receptors were expressed in native or heterologous sys-
tems. For example, the correlation coefficients for α2β
receptors between taurine efficacy and glycine current
density in individual systems were 0.11, 0.13, 0.19, 0.05,
and 0.31 for HEK, L-cells, 3T3 cells, MDCK cells, and amy-
gdala neurons, respectively (P >> 0.05). Thus, while there
is clearly a difference in expression level between both the
systems as well as between individual cells in a given sys-
tem, this particular characteristic cannot account for the
apparent taurine efficacy.
The agonist-binding site is not affected by expression 
system
There are a variety of possible mechanisms to account for
the disparities in partial agonist pharmacology between
two expression systems. One way to address this is to
examine competitive antagonist binding properties in
HEK and L-cells. We therefore examined the potency of
the glycine receptor competitive antagonist strychnine in
both systems. Following a 30 second pretreatment with
the antagonist [2], we co-applied strychnine and an EC50
concentration of glycine. The strychnine KB was estimated
for HEK and L-cells expressing either the GlyRα2  or
GlyRα2+β subunits using the Cheng-Prusoff relationship
(see Methods). This relationship takes into account the
divergent Hill-slope and potencies for glycine found in
these two expression systems. Receptors composed of the
GlyRα2 subunit (Fig. 4A) had very similar KB values when
expressed in either HEK (KB = 49 ± 8 nM, n = 11) or L-cells
(KB = 38 ± 7 nM, n = 16; Fig. 4C). The same was true for
cells expressing the GlyRα2β subunits where strychnine
apparent affinity was 32 ± 7 nM (n = 10) in HEK cells and
38 ± 8 nM (n = 10) in L-cells. Two-way ANOVA did not
reveal any significant effect of either system or subunit
composition. Since strychnine is a competitive antagonist
and site-directed mutation studies suggests that strych-
nine and glycine interact with overlapping regions of the
receptor [14-16], our results strongly suggest that func-
tional strychnine affinity, and hence the general structure
of the agonist binding pocket, was not substantially influ-
ence by expression system.
Cytoskeletal components influence glycine receptor 
pharmacology
A third possible mechanism for reduced efficacy in L-cells
compared to HEK cells or neurons could be related to
intracellular factors that influence channel gating [17].
This hypothesis was examined by disrupting the
cytoskeletal protein tubulin, which has been shown to be
important for glycine receptor localization [18]. Direct
application of 100 µM colchicine did not elicit any mem-
brane currents. Furthermore, acute application of 100 µM
colchicine and an EC50 concentration of glycine (300 µM)
did not significantly affect glycine-gated currents them-
selves. Glycine currents were 17.3 ± 2.3 pA/pF while gly-
cine+colchicine currents were 16.7 ± 2.2 pA/pF (p > 0.5,
paired two-tail t-test, n = 7).
The relative efficacy of β-alanine and taurine was exam-
ined in HEK cells expressing α2β subunits following 30
min incubation with 100 µM colchicine at 37°C, enough
time to allow irreversible tubulin disruption [19]. As an
additional control, γ-lumicolchicine, an inactive analog of
colchicine [20], was also used to treat α2β-expressing HEK
cells (Fig 4A). These brief treatments had no obvious effect
on the survival of untransfected cells. There was a trend for
colchicine treatment to reduce the overall current density
at 300 µM glycine, 56.7 ± 9.1 pA/pF in control cells (n =
8), 41.2 ± 2.3 pA/pF in colchicine-treated cells (n = 10),
and 50.1 ± 9.9 pA/pF (n = 6) in γ-lumicolchicine-treated
cells; however, this was not significant (p > 0.05, ANOVA)
and was probably not related to any direct action of colch-
icine given that the glycine current density was also
slightly reduced in α2β-expressing cells exposed to γ-lum-
icolchicine compared to controls. However, the efficacy of
both taurine (p < 0.01, One-way ANOVA) and β-alanine
(p < 0.05, ANOVA) were significantly decreased by colch-
icine but not γ-lumicolchicine treatment. Taurine efficacy
was 33 ± 6% of glycine in controls, 13 ± 3% following col-
chicine, and 28 ± 3% following γ-lumicolchicine. Simi-
larly, β-alanine efficacy was 70 ± 7% of glycine in controls,
49 ± 6% following colchicine, and 72 ± 7% following γ-
lumicolchicine. Similar treatment of α2-expressing HEK
cells with colchicine (Fig. 4B) did not reveal any signifi-
cant effect on glycine current density (54 ± 14 pA/pF in
controls, 60 ± 15 pA/pF in treated), on taurine efficacy (34
± 16% in controls vs. 38 ± 10% in treated), or on β-
alanine efficacy (71 ± 12% in controls vs. 86 ± 8% in
treated). Cholchicine treatment also significantly reduced
β-alanine efficacy in L-cells expressing GlyRα2β (23 ± 2%
in controls vs. 12 ± 3% in treated, P < 0.05, t-test) but not
in GlyRα2-expressing L-cells (Fig. 4C). We did not attempt
to examine taurine in L-cells treated with colchicine given
the exceptionally low efficacy of receptors expressed in
this cell line.
Because the glycine receptor- and tubulin-binding protein
gephyrin provides an obvious link between the receptor
and the tubulin cytoskeleton, we used western analysis of
HEK and L-cell lysates with a gephyrin monoclonal anti-
body specific for the C-terminus. These experiments
revealed that gephyrin-like immunoreactivity was
expressed in both expression systems (Fig. 4D). Notably,BMC Pharmacology 2004, 4:16 http://www.biomedcentral.com/1471-2210/4/16
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The association of glycine receptors with the tubulin-cytoskeleton may influence partial agonist efficacy Figure 4
The association of glycine receptors with the tubulin-cytoskeleton may influence partial agonist efficacy. (A) Tubulin depolym-
erization with colchicine decreased both taurine and β-alanine efficacy of α2β glycine receptors expressed in HEK 293 cells. 
Cells were treated with 100 µM colchicine or γ-lumicolchicine at 37°C for 30 minutes. The graph shows the partial agonist effi-
cacy as a fraction of the maximal glycine response. For taurine (), colchicine treatment reduced apparent efficacy from 33 ± 
6% in control cells (n = 8) to 13 ± 3% in treated cells (n = 10). γ-lumicolchicine, an inactive analogue of colchicine, had no effect 
on taurine efficacy (29 ± 9%, n = 5, ** – P < 0.01 from ANOVA). For β-alanine (■ ), efficacy was reduced from 70 ± 7% in vehi-
cle-treated cells (n = 8) or 67 ± 8% in γ-lumicolchicine-treated cells (n = 5) to 49 ± 6% in cholchicine-treated cells (n = 10, * – 
P < 0.05, ANOVA). (B) Colchicine treatment does not influence partial agonist efficacy of the GlyRα2 homomeric channels. 
Taurine () efficacy was 34 ± 15% in control GlyRα2 cells (n = 4) and was 38 ± 10% in colchicine-treated cells (n = 5, P >> 0.05 
t-test). Similarly, β-alanine efficacy was 72 ± 12% and 86 ± 8% in the same control and treated cells, respectively (P >> 0.05, t-
test). (C) Colchicine treatment decreases β-alanine efficacy in L-cells expressing GlyRα2β heteromeric channels (■ ), but not 
those expressing GlyRα2 homomeric channels (). For the GlyRα2β channels, colchicine treatment significantly reduced effi-
cacy from 23 ± 2% (n = 7) to 12 ± 3% (n = 3, P < 0.05 t-test). (D) Gephyrin-like immunoreactivity was detected in both cells 
lines using 20 and 40 µg of whole cell lysate. * – denotes expected gephyrin mobility (approx. 100 kD).
A
C
B
127kD
85kD
*
HEK L HEK L
40µ µ µ µg2 0 µ µ µ µg
Gephyrin IR
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a ca. 100 kD band dominated the HEK cell gephyrin
immunoreactivity, while multiple bands of varying
intensity could be seen in lysate from L-cells. When taken
with our colchicine data, differences in glycine receptor
pharmacology between α2β receptors expressed in HEK
and L-cells may be partially due to distinct, system-
dependent interactions with distinct isoforms of the
cytoskeletal protein gephyrin.
Discussion
We have expressed several the 'embryonic' (α2 homo-
meric) and 'forebrain' (α2β heteromeric) isoforms in two
distinct expression systems to understand the influence of
endogenous and exogenous factors on receptor partial
agonist pharmacology. Although the pharmacology of the
'embryonic' GlyRα2 isoform and the 'adult spinal' isoform
(GlyRα1β) have been explored more frequently in the lit-
erature, the pharmacology of GlyRα2β receptors has
remained largely unexplored. Despite this, there is strong
evidence that the adult 'forebrain' isoforms, specifically in
the rat basolateral amygdala, is indeed α2β [4]. The cur-
rent study indicates a general trend for decreased apparent
affinity and reduced relative efficacy of agonists when
receptors consist of the α2β subunits compared to their
homomeric α2 counter parts.
We were particularly surprised to find that receptors
expressed in different expression systems possessed mark-
edly different partial agonist efficacies. The remainder of
our study focused on identifying extrinsic factors that
influence difference in ligand-gated receptor pharmacol-
ogy in distinct expression systems. While differences in
efficiency of cDNA expression/transfection between sys-
tems could explain such differences, the expression levels
of GlyRα2β receptors measured by current density was not
correlated with taurine efficacy across several different cell
types or within any given system. Importantly, the efficacy
of β-alanine and taurine in HEK cells agree with previous
findings where cells expressing GlyRα2 show almost full
efficacy for taurine and β-alanine [21]. Similarly, distinct
ligand binding characteristics of receptors expressed in
different expression systems seemed to be another possi-
ble mechanism governing agonist efficacy or potency. For
the glycine receptor, the binding site for the competitive
antagonist strychnine is believed to be adjacent to the ago-
nist-binding site, sterically hindering agonist binding. A
gross alteration in the agonist binding pocket, particularly
one that hindered agonist binding, would most likely
affect strychnine binding as well. To examine this, strych-
nine KB was calculated for GlyRα2 and GlyRα2β isoforms
expressed in both HEK and L-cells. In order to decrease the
error in estimating KB, a derivation of the Cheng-Prusoff
equation was used that takes in account variations in the
slopes of the inhibition curves [22]. Differences in KB were
negligible between expression systems, indicating the
strychnine binding site, and presumably the agonist bind-
ing site, was altogether similar in these different systems.
Differences in pharmacology between systems therefore
cannot be explained by substantial alterations in the ago-
nist/competitive antagonist binding pocket.
Receptor gating is another mechanism by which receptor
function may be altered. Cytoskeletal elements have been
shown to play a crucial role in neurotransmitter receptor
clustering [17] and may have a role in receptor function as
well. For example, cytoskeletal stabilization has been
shown to reduce Ca++-dependent inactivation of Ca++
channels in snail ganglia [23]; and, actin has been shown
to modulate several different types of membrane ion
channel [24-26]. Cytoskeletal depolymerization has also
been found to inhibit the function of GABAA receptors,
which share significant sequence homology and func-
tional characteristics with strychnine-sensitive glycine
receptors [27]. And the tubulin-gephyrin-glycine receptor
interaction is critical for establishing functional glyciner-
gic synapses [28]. The current study suggests that cytoskel-
etal elements may play a functional role in α2β glycine
receptor pharmacology as well. β-containing glycine
receptors are intimately associated with the tubulin-asso-
ciated protein gephyrin [29] via the gephyrin binding site
that lies within the intracellular domain of this subunit
[30]. In our studies, the efficacy of both taurine and β-
alanine were reduced in cells expressing GlyRα2β subu-
nits. This despite the finding that gephyrin-like immuno-
reactivity in L-cells was apparently distinct from that in
HEK cells, suggesting that distinct cytoskeletal compo-
nents in these systems may have profound influence over
GlyR α2β pharmacology. This is further supported by sug-
gestions that gephyrin may exist in multiple, tissue-spe-
cific isoforms with potentially distinct functional roles
[31-33]. It should be noted however that colchicine treat-
ment of α2β-expressing HEK cells did not suppress partial
agonist efficacy to a level that approached that found in L-
cells or 3T3-fibroblasts. Given that colchicine had no per-
ceptible effect of α2-homomeric channels expressed in
HEK cells, our results suggest that additional system-
dependent factors may have a more pronounced influ-
ence on the partial agonist pharmacology of strychnine-
sensitive glycine receptors.
Conclusions
It is of particular interest that the β subunit appears to play
a functional role in the pharmacology of α2-containing
receptors regardless of expression system. For example,
the beta subunit decreased the apparent efficacy of the
partial agonists. Since the β-subunit itself does not appre-
ciably interact with the competitive antagonist strychnine
[34], these results are at least consistent with some allos-
teric interaction between the β-subunit and the agonist
binding site present the α subunit. This may indicate thatBMC Pharmacology 2004, 4:16 http://www.biomedcentral.com/1471-2210/4/16
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α2β glycine receptors in the forebrain may be distinguish-
able from other receptor isoforms given the appropriate
pharmacologic agent. Although cytoskeletal components
potentially play some role for these 'forebrain' receptors,
there appear to be other 'extrinsic' factors governing
expression system-dependent effects on agonist pharma-
cology. Since it is conceivable that such factors may be dif-
ferentially distributed between different forebrain regions,
the large apparent differences between glycine receptor
pharmacology reported by various studies may not neces-
sarily depend upon differential expression of glycine
receptor subunits per se. At the very least, our findings
suggest that great care should be taken when utilizing dif-
ferent expression systems to develop screens for novel
pharmacophores acting on this receptor.
Methods
Cell culture and transfection
HEK 293 (TSA 201; gift from Michael J. Davis, Dept. Med.
Physiol., Texas A&M Univ. Health Science Center, College
Station, USA), mouse L-cells (NCTC-929; American Type
Culture Collection), NIH/3T3 fibroblasts (ATCC), and
MDCK cells (gift from Alan Parrish, Dept. Med. Pharma-
col. & Toxicol., Texas A&M Univ. Health Sci. Center) were
grown in Dulbecco's modified Eagle's medium (DMEM,
SIGMA) with 10% fetal bovine serum (HyClone Labora-
tories, Logan, UT, USA) and 1X penicillin/streptomycin
(Life Technologies) on Thermanox cover slips in 35 mm
culture dishes. Cells were transfected during log-phase
growth (30–50% confluent) using the Superfect reagent
(Qiagen, Valencia, CA, USA), according to manufacturers
instructions. Rat glycine receptor α2 and β subunits were
cloned previously [4]. Briefly, a total of 2–3 µg of plasmid
constructs was added to 100 µL serum-free media along
with 10 µL Superfect reagent, vortexed for several seconds,
and incubated for 10 minutes to allow DNA/liposome
formation. Standard media (600 µL) was added and this
mixture applied the cells and incubated for 2–3 hours at
37°C. The cells were subsequently washed twice with
phosphate-buffered saline, fresh media was applied and
cells were then incubated for 24–48 hours prior to record-
ing. Cells were co-transfected with green fluorescent pro-
tein (pEGFP-C1, Clontech, Pal Alto, CA, USA) to identify
transfected cells before recording. Mass ratios of 1:1:5
were used in the GFP:α2:β transfections. An equal mass of
the cloning vector pCI (Promega Corp) replaced the β
subunit when examining α2 homomeric channels.
Electrophysiology
Whole cell recordings were performed at room tempera-
ture using standard patch-clamp techniques and the axo-
patch-1D amplifier (Axon Instruments, Inc., Foster City
CA, USA) in the voltage clamp mode. Gigaohm seals were
formed using patch pipettes made from borosilicate glass
(World Precision Instruments, Sarasota FL, USA). For
most experiments, the internal solution contained (in
mM): CsCl 100, EGTA 11, HEPES 10, CaCl2 1, Mg-ATP 4,
pH 7.2 with methane sulfonic acid; adjusted to 290–295
mmol kg-1 with sucrose. Whole cell capacitance and series
resistance was manually compensated after opening the
cell. Cells were continuously bath perfused with a HEPES-
buffered saline (in mM): NaCl 150, Glucose 10, HEPES
10, KCl 2.5, CaCl2 2.5 MgCl2 1.0, pH 7.4, 305–320 mmol
kg-1 Data will be analyzed off-line using pClamp software
(Axon). Numerical analysis was performed using com-
mercially available software. Independent student's t-test
and two-way ANOVA were used for comparisons where
appropriate; and statistical significance was based on p <
0.05. Concentration-response curves were generated from
fits of data to a standard logistic equation as previously
described (McCool & Botting, 2000). To derive KB from
functional IC50 and EC50 data, the Cheng-Prusoff equation
was used:
where S = hillslope of agonist curve, A = concentration of
agonist, EC50 = half-maximal agonist concentration, and
IC50 = half-maximal antagonist concentration.
Drugs
Stocks of glycine, taurine, β-alanine, strychnine (Tocris)
and colchicine (SIGMA) were prepared fresh each day.
Agonists and antagonists were applied for 4–10 sec from
an array of eight HPLC-grade capillary tubes (150 µm i.d.;
Hewlett Packard Analytical Direct) placed within 100 µm
of the cell of interest.
Western analysis
Cells were cultured, transfected as stated above except in
10 cm Petri dishes, and harvested by scrapping with 500
µL of lysis buffer (10 mM Tris pH 7.5, 1% SDS). Proteins
were quantified using the Bradford assay and loaded onto
8–10% SDS-polyacrylamide gels, separated, and trans-
ferred to a nitrocellulose membrane (Hybond C, Amer-
sham). The membrane was blocked overnight TBS (200
mM NaCl, 10 mM Tris pH 7.5) containing 0.2% Tween-
20 and 10% low-fat dry milk. Blots were then incubated
in TBS/0.1% Tween-20 containing primary GlyR antibody
(monoclonal GlyR4a antibody, 1:200, Alexis Biochemi-
cals) and monoclonal anti-gephyrin antibody (1:2000,
Transduction Laboratories) for two hours at room temper-
ature. After several washes, the HRP-coupled rabbit anti-
mouse secondary antibody (SIGMA) was added for one
hour (1:2000). The detection was performed by the ECL
method (Amersham).
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